Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease
Identifieur interne : 002869 ( Main/Exploration ); précédent : 002868; suivant : 002870Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease
Auteurs : Thomas Müller [Allemagne] ; Dirk Woitalla [Allemagne] ; Oliver Goetze [Allemagne, Suisse] ; Christoph Erdmann [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-07-30.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (therapeutic use), Breath Tests, Caprylates (administration & dosage), Caprylates (pharmacokinetics), Carbidopa (administration & dosage), Carbidopa (pharmacokinetics), Carbidopa (therapeutic use), Carbon Isotopes (analysis), Catechol O-Methyltransferase Inhibitors, Catechols (pharmacology), Drug Interactions, Drug Therapy, Combination, Entacapone, Enzyme Inhibitors (pharmacology), Female, Gastric Emptying (drug effects), Human, Humans, Intestinal Absorption (drug effects), Levodopa, Levodopa (administration & dosage), Levodopa (pharmacokinetics), Levodopa (therapeutic use), Male, Middle Aged, Nervous system diseases, Nitriles (pharmacology), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson disease, Parkinson's disease, Solubility, absorption, entacapone, levodopa.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Caprylates, Carbidopa, Levodopa.
- chemical , analysis : Carbon Isotopes.
- chemical , pharmacokinetics : Antiparkinson Agents, Caprylates, Carbidopa, Levodopa.
- chemical , pharmacology : Catechols, Enzyme Inhibitors, Nitriles.
- chemical , therapeutic use : Antiparkinson Agents, Carbidopa, Levodopa.
- drug effects : Gastric Emptying, Intestinal Absorption.
- drug therapy : Parkinson Disease.
- metabolism : Parkinson Disease.
- Adult, Aged, Breath Tests, Catechol O-Methyltransferase Inhibitors, Drug Interactions, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Solubility.
Abstract
Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol‐O‐methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD derivatives. LD metabolism correlates to the one of 13C‐sodium‐octanoate, which is employed in breath tests to measure gastric emptying velocity. Objectives were to investigate the impact of COMT inhibition on the recovery rate of 13C‐sodium‐octanoate in parkinsonian patients, who received first 100 mg LD/Carbidopa (CD) and the next day 100 mg LD/CD/EN combined with 13C‐sodium‐octanoate in each case. The recovery rate of 13C‐sodium‐octanoate was significant higher during the LD/CD/EN–compared with the LD/CD condition. COMT inhibition combined with LD/DDI improves absorption of a co‐administered salt probably due to a COMT inhibition induced basic environment in gastrointestinal membranes. This improves dissolution and absorption of acids and salts. Thus it may enhance absorption of LD itself. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22176
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E01
- to stream Istex, to step Curation: 000E01
- to stream Istex, to step Checkpoint: 001425
- to stream PubMed, to step Corpus: 002186
- to stream PubMed, to step Curation: 002186
- to stream PubMed, to step Checkpoint: 002311
- to stream Ncbi, to step Merge: 002177
- to stream Ncbi, to step Curation: 002177
- to stream Ncbi, to step Checkpoint: 002177
- to stream Main, to step Merge: 003447
- to stream PascalFrancis, to step Corpus: 001160
- to stream PascalFrancis, to step Curation: 001B59
- to stream PascalFrancis, to step Checkpoint: 001266
- to stream Main, to step Merge: 003874
- to stream Main, to step Curation: 002869
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease</title><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></author><author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name></author><author><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name></author><author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22176</idno><idno type="url">https://api.istex.fr/document/A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E01</idno><idno type="wicri:Area/Istex/Curation">000E01</idno><idno type="wicri:Area/Istex/Checkpoint">001425</idno><idno type="wicri:doubleKey">0885-3185:2008:Muller T:entacapone:improves:absorption</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18546331</idno><idno type="wicri:Area/PubMed/Corpus">002186</idno><idno type="wicri:Area/PubMed/Curation">002186</idno><idno type="wicri:Area/PubMed/Checkpoint">002311</idno><idno type="wicri:Area/Ncbi/Merge">002177</idno><idno type="wicri:Area/Ncbi/Curation">002177</idno><idno type="wicri:Area/Ncbi/Checkpoint">002177</idno><idno type="wicri:Area/Main/Merge">003447</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0417086</idno><idno type="wicri:Area/PascalFrancis/Corpus">001160</idno><idno type="wicri:Area/PascalFrancis/Curation">001B59</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001266</idno><idno type="wicri:doubleKey">0885-3185:2008:Muller T:entacapone:improves:absorption</idno><idno type="wicri:Area/Main/Merge">003874</idno><idno type="wicri:Area/Main/Curation">002869</idno><idno type="wicri:Area/Main/Exploration">002869</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease</title><author><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Joseph Hospital Berlin‐Weißensee, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author><author><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author><author><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Medicine I, St. Josef Hospital, Ruhr‐University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Suisse</country><wicri:regionArea>University Hospital Zurich, Division of Gastroenterology and Hepatology, Zürich</wicri:regionArea><placeName><settlement type="city">Zurich</settlement><region nuts="3" type="region">Canton de Zurich</region></placeName></affiliation></author><author><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum</wicri:regionArea><wicri:noRegion>Bochum</wicri:noRegion><wicri:noRegion>Bochum</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-07-30">2008-07-30</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1458">1458</biblScope><biblScope unit="page" to="1461">1461</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6</idno><idno type="DOI">10.1002/mds.22176</idno><idno type="ArticleID">MDS22176</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Breath Tests</term><term>Caprylates (administration & dosage)</term><term>Caprylates (pharmacokinetics)</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (pharmacokinetics)</term><term>Carbidopa (therapeutic use)</term><term>Carbon Isotopes (analysis)</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Catechols (pharmacology)</term><term>Drug Interactions</term><term>Drug Therapy, Combination</term><term>Entacapone</term><term>Enzyme Inhibitors (pharmacology)</term><term>Female</term><term>Gastric Emptying (drug effects)</term><term>Human</term><term>Humans</term><term>Intestinal Absorption (drug effects)</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (pharmacokinetics)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Nitriles (pharmacology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Solubility</term><term>absorption</term><term>entacapone</term><term>levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Caprylates</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Carbon Isotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Caprylates</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Catechols</term><term>Enzyme Inhibitors</term><term>Nitriles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gastric Emptying</term><term>Intestinal Absorption</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Breath Tests</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Drug Interactions</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Solubility</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Entacapone</term><term>Homme</term><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol‐O‐methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD derivatives. LD metabolism correlates to the one of 13C‐sodium‐octanoate, which is employed in breath tests to measure gastric emptying velocity. Objectives were to investigate the impact of COMT inhibition on the recovery rate of 13C‐sodium‐octanoate in parkinsonian patients, who received first 100 mg LD/Carbidopa (CD) and the next day 100 mg LD/CD/EN combined with 13C‐sodium‐octanoate in each case. The recovery rate of 13C‐sodium‐octanoate was significant higher during the LD/CD/EN–compared with the LD/CD condition. COMT inhibition combined with LD/DDI improves absorption of a co‐administered salt probably due to a COMT inhibition induced basic environment in gastrointestinal membranes. This improves dissolution and absorption of acids and salts. Thus it may enhance absorption of LD itself. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Suisse</li></country><region><li>Berlin</li><li>Canton de Zurich</li></region><settlement><li>Berlin</li><li>Zurich</li></settlement></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name></region><name sortKey="Erdmann, Christoph" sort="Erdmann, Christoph" uniqKey="Erdmann C" first="Christoph" last="Erdmann">Christoph Erdmann</name><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name><name sortKey="Muller, Thomas" sort="Muller, Thomas" uniqKey="Muller T" first="Thomas" last="Müller">Thomas Müller</name><name sortKey="Woitalla, Dirk" sort="Woitalla, Dirk" uniqKey="Woitalla D" first="Dirk" last="Woitalla">Dirk Woitalla</name></country><country name="Suisse"><region name="Canton de Zurich"><name sortKey="Goetze, Oliver" sort="Goetze, Oliver" uniqKey="Goetze O" first="Oliver" last="Goetze">Oliver Goetze</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002869 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002869 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A6B9BF2A4B17E76BA549BDD0BF27D734BF8610B6
|texte= Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |